Trial Profile
Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Sep 2018 Status changed from active, no longer recruiting to completed.
- 16 Jun 2015 Planned End Date changed from 1 Jul 2014 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
- 16 Jun 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Jul 2016 as reported by ClinicalTrials.gov record.